Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? (RIPCORD 2)

8 de agosto de 2019 atualizado por: University Hospital Southampton NHS Foundation Trust

A Randomised Controlled Trial to Compare Routine Pressure Wire Assessment With Conventional Angiography in the Management of Patients With Coronary Artery Disease.

A randomised controlled trial to compare two strategies for the investigation of coronary artery disease at the time of angiography. Patients will be randomised to conventional angiography or additional, routine pressure wire assessment - measuring fractional flow reserve (FFR) - in all main vessels judged as being of sufficient vessel calibre to allow percutaneous coronary intervention (PCI) (experimental arm).

Visão geral do estudo

Descrição detalhada

The study will recruit patients undergoing angiography for the investigation of stable angina or for the assessment of a recent, but stabilised, non-ST elevation acute coronary syndrome event. Eligible patients who provide written informed consent will be randomised to conventional angiography or additional, routine pressure wire assessment - measuring fractional flow reserve (FFR) - in all main vessels judged as being of sufficient vessel calibre to allow percutaneous coronary intervention (PCI) (experimental arm). The study pragmatic design allows investigators to conduct all diagnostic and therapeutic management in accordance with prevailing best practice patterns. Study outcome measures will examine resource utilisation, patient reported quality of life and clinical events at 1 year.

Tipo de estudo

Intervencional

Inscrição (Real)

1100

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Bristol, Reino Unido, BS2 8HW
        • Bristol Heart Institute - University Hospitals Bristol NHS Foundation Trust
    • Dorset
      • Bournemouth, Dorset, Reino Unido, BH7 7DW
        • Royal Bournemouth Hospital - The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
    • East Sussex
      • Brighton, East Sussex, Reino Unido, BN2 5BE
        • Brighton and Sussex University Hospitals NHS Trust
    • Hampshire
      • Portsmouth, Hampshire, Reino Unido, PO6 3LY
        • Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust
      • Southampton, Hampshire, Reino Unido, SO16 6YD
        • Southampton General Hospital - University Hospitals Southampton NHS Foundation Trust
    • Lancashire
      • Blackburn, Lancashire, Reino Unido, BB2 3HH
        • Royal Blackburn Teaching Hospital - East Lancashire Hospitals NHS Trust
    • Merseyside
      • Liverpool, Merseyside, Reino Unido, L14 3PE
        • Liverpool Heart and Chest Hospital NHS Foundation Trust
    • Northumberland
      • Newcastle upon Tyne, Northumberland, Reino Unido, NE7 7DN
        • Freeman Hospital - Newcastle Hospitals
    • Nottinghamshire
      • Mansfield, Nottinghamshire, Reino Unido, NG17 4JL
        • King's Mill Hospital - Sherwood Forest Hospitals NHS Foundation Trust
      • Nottingham, Nottinghamshire, Reino Unido, NG5 1PB
        • City Hospital - Nottingham University Hospitals NHS Trust
    • Scotland
      • Glasgow, Scotland, Reino Unido, G81 4DY
        • Golden Jubilee National Hospital
    • South Yorkshire
      • Sheffield, South Yorkshire, Reino Unido, S5 7AU
        • Northern General Hospital - Sheffield Teaching Hospitals
    • Staffordshire
      • Stoke-on-Trent, Staffordshire, Reino Unido, ST4 6QG
        • Royal Stoke University Hospital - University Hospitals of North Midlands
    • West Midlands
      • Birmingham, West Midlands, Reino Unido, B15 2TH
        • Queen Elizabeth Hospital - University Hospitals Birmingham NHS Foundation Trust
    • West Yorkshire
      • Wakefield, West Yorkshire, Reino Unido, WF1 4DG
        • Pinderfields Hospital - The Mid Yorkshire Hospitals NHS Trust
    • Yorkshire
      • Hull, Yorkshire, Reino Unido, HU16 5JQ
        • Castle Hill Hospital - Hull and East Yorkshire Hospitals NHS Trust
      • Leeds, Yorkshire, Reino Unido, LS1 3EX
        • Leeds General Infirmary - Leeds Teaching Hospitals NHS Trust

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

· Inclusion criteria

o Outline Initial Inclusion Criteria (before entry to cath lab):

Patient scheduled for coronary angiography for the:

  • Elective investigation of known or suspected coronary artery disease OR
  • Urgent investigation of a recent but stabilised, non-ST elevation acute coronary syndrome event

    o Outline Angiographic Inclusion Criterion (after angiography):

  • Presence of significant coronary disease defined as:

Any stenosis >30% reduction in luminal diameter, by visual estimate, in at least one vessel (main or branch) of sufficient calibre to permit the potential performance of PCI - approximately 2.25 mm diameter.

  • Key Exclusion Criteria

    • Screening phase exclusion criteria:

      • ≤ 18 years of age
      • Previous enrolment in this trial
      • Currently enrolled into another study unless co-enrolment approved by Chief Investigator (CI) and the clinical trials unit (CTU)
      • Inability to provide informed consent
      • Residence outside the United Kingdom (UK) or other issues limiting the ability to secure clinical follow-up data to one year
      • Non-cardiac pathology that may limit survival in the next year
      • Clear contraindication to potential future management with CABG or PCI (patients should be a potential candidate for medical therapy or revascularisation with either PCI or surgery)
      • Heart valve disease of sufficient import to consider valve replacement or other intervention as part of an index management strategy
      • Hypertrophic cardiomyopathy
      • Previous coronary artery surgery of any type
      • Known chronic renal impairment with a current estimated glomerular filtration rate (eGFR) of < 45
      • Anaemia with a current measured haemoglobin of < 100
      • Angiography performed in the context of an ST elevation myocardial infarction event
      • Any patient who at the time of planned angiography manifests haemodynamic instability, or recurrent sustained ventricular arrhythmia, or Mobitz type II or complete heart block
      • Any patient who at the time of planned angiography manifests unstable chest pain symptoms at rest or has required the continuing use of intravenous nitrates or regular opioid analgesia to control symptoms
      • Continuing use of intravenous glycoprotein 2b/3a (GP2b3a) agents before entry to the catheterisation laboratory
      • Known intolerance, hypersensitivity or contraindication to adenosine - including significant reversible airways disease
      • Additional investigations planned (or deemed likely to be required) for the assessment of myocardial ischaemia or viability. Examples of proposed tests that would constitute an exclusion criterion would include, but are not limited to, exercise tolerance testing, stress echocardiography, cardiac MRI viability or perfusion scanning or nuclear myocardial perfusion scanning.
      • Active bleeding at the time of planned index angiography
      • Pregnant women
    • Angiographic phase exclusion criteria:

      • Single vessel occlusive coronary disease (TIMI flow <3) as sole disease
      • Patient not suitable for the immediate performance of a pressure wire assessment of all major vessels for any reason, for example:

        • Patient discomfort
        • Change in the clinical condition or complication of angiography requiring termination of the procedure or immediate intervention
        • Significant use of radiographic contrast or X-Ray exposure during the initial angiography
        • Inadequate angiographic images or failure to intubate any of the coronary vessels
        • Aorto-ostial disease that would preclude accurate assessment of FFR
        • Insufficient laboratory time
        • Uncertain availability of key clinical and trial staff
        • PW use in coronaries declared unsafe (e.g. tight or long disease)
        • PW use in coronaries declared unsuitable (e.g. distal disease or complete cross-filling)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Diagnóstico
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Sem intervenção: Conventional angiography
Routine angiography will be performed according to local best practice
Experimental: Routine Measurement of FFR
Additional investigation with the measurement of FFR in all major vessels
FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow <3 will not be examined but will be 'awarded' an FFR value of 0.5
Outros nomes:
  • Pressure wire assessment

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Primary Economic Outcome Measure
Prazo: One year
Resource utilisation as determined by hospital care costs at one year; All hospital admissions will be tracked using national hospital episode statistics; the cost of each episode will be derived from a cost model using standard UK tariffs. This analysis will compare the mean (or median) of the total hospital costs recorded for each patient over the 12 month follow-up period.
One year
Primary Quality of Life Outcome Measure
Prazo: One year
Patient reported quality of life at one year using the EQ-5D health questionnaire.
One year

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Mortalidade por todas as causas
Prazo: Um ano
Um ano
Management strategy information
Prazo: Reported once: Single declaration at index procedure after randomisation
· Proportion of vessels deemed to demonstrate flow-limiting disease and targeted for revascularisation in the declared initial management strategy.
Reported once: Single declaration at index procedure after randomisation
Management strategy information
Prazo: Reported once: Single declaration at index procedure after randomisation
· Proportion of patients scheduled for management with medical therapy, percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) in the declared initial management strategy.
Reported once: Single declaration at index procedure after randomisation
Angina symptoms
Prazo: One year
• Angina symptoms as reported by the research team after the 12 month contact, described by Canadian Cardiovascular Society Grade.
One year
Angina symptoms
Prazo: One year
• Angina symptoms as reported by the patient with private completion of a screening form at 12 months, described by Canadian Cardiovascular Society Grade.
One year
Number of hospitalisation events
Prazo: One year
One year
Total hospital days
Prazo: One year
One year
Hospitalisation events
Prazo: One year
Hospitalisation events coded as cerebro-vascular accident (CVA).
One year
Hospitalisation events
Prazo: One year
Hospitalisation events coded as myocardial infarction.
One year
Hospitalisation events
Prazo: One year

Hospitalisation events coded as Coronary revascularisation. This analysis will involve a pre-specified subgroup analysis of:

  • Planned revascularisation - if declared as the index strategy.
  • All additional revascularisation events.
One year

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Nicholas Curzen, BM PhD FRCP, University Hospital Southampton NHS Foundation Trust
  • Investigador principal: Rod H Stables, MA, DM, BM BCH, FRCP, Liverpool Heart and Chest Hospital NHS Foundation Trust

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de setembro de 2016

Conclusão Primária (Antecipado)

1 de dezembro de 2019

Conclusão do estudo (Antecipado)

1 de março de 2020

Datas de inscrição no estudo

Enviado pela primeira vez

6 de julho de 2016

Enviado pela primeira vez que atendeu aos critérios de CQ

1 de setembro de 2016

Primeira postagem (Estimativa)

8 de setembro de 2016

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de agosto de 2019

Última atualização enviada que atendeu aos critérios de controle de qualidade

8 de agosto de 2019

Última verificação

1 de agosto de 2019

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever